[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-502117-105":59,"doc-detail-502117-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-ccatenhancer-binding-protein-b3-axis-by-1-piperidin-propionic-acid-as-a-new-targeted-therapy-of-non-alcoholic-steatohepatitis","Inhibition of CCAT/Enhancer-Binding Protein B3 axis by 1-Piperidin Propionic Acid as a new targeted therapy of Non-Alcoholic Steatohepatitis","","Non-Alcoholic Fatty Liver Disease (NAFLD) is a leading cause of chronic liver disease worldwide, progressing from simple steatosis to non-alcoholic steatohepatitis (NASH). SerpinB3, proposed as a hepatokine, may modulate inflammation, fibrosis, and insulin resistance during NASH development. The study evaluates a targeted SerpinB3 inhibitor, 1-Piperidin Propionic Acid (1-PPA), in vitro and in vivo NASH models, assessing histology and expression of pro-fibrotic and pro-inflammatory markers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-ccatenhancer-binding-protein-b3-axis-by-1-piperidin-propionic-acid-as-a-new-targeted-therapy-of-non-alcoholic-steatohepatitis/502117/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-ccatenhancer-binding-protein-b3-axis-by-1-piperidin-propionic-acid-as-a-new-targeted-therapy-of-non-alcoholic-steatohepatitis/502117.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-10-03",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition is addressed in this study?","Question",{"text":112,"@type":113},"The study focuses on Non-Alcoholic Steatohepatitis (NASH), a progression of Non-Alcoholic Fatty Liver Disease (NAFLD).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the targeted therapeutic strategy tested?",{"text":117,"@type":113},"It tests a specific SerpinB3 inhibitor, 1-Piperidin Propionic Acid (1-PPA), as a targeted therapy for NASH.",{"name":119,"@type":110,"acceptedAnswer":120},"How was 1-PPA evaluated in the study?",{"text":121,"@type":113},"Histological parameters and gene expression of pro-fibrotic and pro-inflammatory markers were analyzed in vivo, and relevant gene expression was assessed in cell lines in vitro after incubation with SerpinB3 ± 1-PPA.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},502117,1791787775,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81,"preview_page_count":4},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","I n h i b i t i o n o f C C A T / E n h a n c e r-B i n d i n g P r o t e i n b e t a - S e r p i n B 3 a x i s b y 1-P i p e r i d i n e P r o p i o n i c A c i d a s a n e wt a r g e t t h e r a p y o f N o n-A l c o h o l i c  \nS t e a t o h e p a t i t i s  \nF. PROTOPAPA 1 , G. M. VILLANO2 , E. NOVO 1 , C. TURATO4 , S.QUARTA 3 , M. G. RUVOLETTO 3 , A. BIASIOLO 3 , M. CHINELLATO 3 , A. MARTINI 3 , E. TREVELLIN 3 , M. GRANZOTTO 3 , S. CANNITO 1 , L. CENDRON 5 , S. DE SIERVI4 , 3M. GUIDO 3 , M. PAROLA 1 , R. VETTOR 3 , P. PONTISSO 3  \n1Department of Clinical and Biological Sciences, University of Torino, Italy; 2Department of Surgical, Oncological and Gastroenterological Sciences; University of Padova, Italy; 3Department of Medicine, University of Padova, Italy; 4Department of Molecular Medicine, University of Pavia, Italy; 5Department of Biology, University of Padova, Italy.  \nIntroduction  \nNon-Alcoholic Fatty Liver Disease (NAFLD) is becoming the major cause of chronic liver disease worldwide, with a 25% prevalence in the general population and a higher prevalence in obese and type II diabetes patients. NAFLD includes a spectrum of liver diseases ranging from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) . The serine protease inhibitor SerpinB3 has been proposed as a novel hepatokine able to modulate liver inflammation, fibrosis as well as insulin resistance during NASH development  \nAim  \nIn the present study, in order to investigate a new targeted therapeutic strategy for NASH, we have tested a specific SerpinB3 inhibitor, the 1-Piperidin Propionic Acid (1-PPA) PPA in in vitro and in vivo models of NASH  \nMethod  \nIn vivo models: analysis of histological parameters and gene expression of pro-fibrotic and pro-inflammatory markers in SerpinB3-transgenic (TG) fed on CDAA diet to induce experimental NASH and injected or not with 1-PPA (70 ng/g) . In vitro models: pro-fibrotic and pro-inflammatory genes were assessed in LX2 and THP1 cell lines, exposed to human SerpinB3 (100ng/ml) alone or with 1-PPA (100ng/ml) after 24 hours incubation  \nConclusions  \nSerpinB3-C/EBP-β axis could be relevant in the development of NASH and the SerpinB3 inhibitor 1-PPA is effective in the control of inflammation and fibrosis in vitro and in NASH models, supporting this approach for a targeted therapy of NASH  \nAcknowledgements  \nWe sincerely thank all the authors for their precious contribution  \nContact information  \nFrancesca Protopapa, PhD student  \nEmail: francesca.protopapa@unito.it  \nDepartment of Clinical and Biological Sciences, University of Torino, Italy  \n1  \n2  \n3  \n5  \n6  \n7  \nResults  \n10x  \nWT CDAA + PPA  \nTG CDAA  \nTG CDAA + PPA  \n2^ -DD ct  \nFigure 1: In TG/SB3 mice fed on CDAA diet 1-PPA administration reduces inflammatory  \ninfiltration  \n4   \n3   \n2   \n1   \n0   \nWT TG  \n2^ -DD ct  \nWT TG  \n2^ -DD ct  \n CDAA  \n CDAA + PPA  \n6   \n4   \n2   \n0   \nWT TG  \nFigure 2: In TG/SB3 mice fed on CDAA diet 1-PPA administration reduces inflammatory mediators transcript levels  \nWT CDAA  \nWT CDAA + PPA  \nTG CDAA  \nTG CDAA + PPA  \nFigure 3: In TG/SB3 mice fed on CDAA diet 1-PPA administration reduces significantly fibrosis  \n2^ -DD ct  \n15  \n10  \n5  \n0  \na-SMA  \nWT TG  \n2^ -DD ct  \n25   \n20   \n15   \n10   \n5   \n0   \nWT TG  \n2^ -DDct  \n CDAA  \n CDAA + PPATGF-b  \nWT TG  \nFigure 4: In TG/SB3 mice fed on CDAA diet 1-PPA administration down-regulates the transcript levels offibrotic mediators  \nScan to download the poster  \nDOI: [10.3252/pso.eu.EASLCONGRESS.2023](10.3252/pso.eu.EASLCONGRESS.2023)  \nMetabo lism, a lcohol and toxicity Francesca Proto papa  \nEASL2023  \nWED--449-YI","cbCaispWG9bam8jR","https://ap.wps.com/l/cbCaispWG9bam8jR","pdf",3238030,"English","# Introduction\n# Aim\n# Method\n# Conclusions\n# Results","[{\"question\":\"What condition is addressed in this study?\",\"answer\":\"The study focuses on Non-Alcoholic Steatohepatitis (NASH), a progression of Non-Alcoholic Fatty Liver Disease (NAFLD).\"},{\"question\":\"What is the targeted therapeutic strategy tested?\",\"answer\":\"It tests a specific SerpinB3 inhibitor, 1-Piperidin Propionic Acid (1-PPA), as a targeted therapy for NASH.\"},{\"question\":\"How was 1-PPA evaluated in the study?\",\"answer\":\"Histological parameters and gene expression of pro-fibrotic and pro-inflammatory markers were analyzed in vivo, and relevant gene expression was assessed in cell lines in vitro after incubation with SerpinB3 ± 1-PPA.\"}]","Inhibition of CCAT/Enhancer-Binding Protein B3 axis by 1-Piperidin Propionic Acid as a new targeted therapy of Non-Alcoholic Steatohepatitis | PDF",1791029383]